Taken together, these profiles suggest a clear dissociation: TIGIT-high CRC aligns with immune activation and inflammatory signaling, whereas CD155-high CRC aligns with proliferative, oncogenic cell cycle circuitry accompanied by relative suppression of immune-response pathways, highlighting biologically distinct contexts for the TIGIT/CD155 axis in CRC. The gene discussed is PVR; the disease is colorectal carcinoma.